Healio Coverage

December 31, 2020
1 min read

Top in hem/onc: Cancer care amid COVID-19, tumor bed boost


Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Healio’s look at how cancer clinic operators prepared for the second wave of COVID-19 cases was the top story in hematology/oncology last week.

Another top story was about data that showed how adding tumor bed boost following conventional or hypofractionated whole-breast irradiation benefitted women with non-low risk ductal carcinoma in situ.

Photo of person receiving chemotherapy
Source: Adobe Stock

Read these and more top stories in hematology/oncology below:

Cancer clinics confident in COVID-19 precautions to protect patients, survivors

As another surge in COVID-19 cases looms, oncology clinic operators said they are much more confident in handling patients who need cancer care. Read more.

Tumor bed boost added to whole-breast irradiation reduces local recurrence rates in ductal carcinoma in situ

The addition of tumor bed boost following conventional or hypofractionated whole-breast irradiation reduced the rate of local recurrence among women with non-low risk ductal carcinoma in situ, according to randomized phase 3 study results. Read more.

Long-term active surveillance safe, viable option for certain men with prostate cancer

Metastasis and prostate cancer-specific death appeared to be rare among men with low-risk and carefully selected intermediate-risk prostate cancer undergoing long-term active surveillance, according to study data published in Journal of Urology. Read more.

FDA grants breakthrough therapy status to LNP023 for paroxysmal nocturnal hemoglobinuria

The FDA granted breakthrough therapy designation to iptacopan (LNP023, Novartis) for the treatment of paroxysmal nocturnal hemoglobinuria. Read more.

FDA grants fast track designation to CPI-613 for acute myeloid leukemia

The FDA granted fast track designation to devimistat (CPI-613, Rafael Pharmaceuticals) for treatment of acute myeloid leukemia, according to the agent’s manufacturer. Read more.